An Open Label Pilot Trial of the Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
Latest Information Update: 21 May 2024
At a glance
- Drugs Pacritinib (Primary) ; Tagraxofusp (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 21 May 2024 New trial record